DK3002298T3 - Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf - Google Patents

Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number: DK3002298T3
Authority: DK; Denmark
Prior art keywords: procedures; factor; monoclonal antibodies; monoclonal; antibodies
Prior art date: 2007-11-21

Application number

DK15189714T

Other languages

English (en)

Inventor

Andras Gruber

Erik Ian Tucker

Stephen Raymond Hanson

David Gailani

Original Assignee

Univ Oregon Health & Science

Univ Vanderbilt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-21

Filing date

2008-11-21

Publication date

2019-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3002298(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-21 Application filed by Univ Oregon Health & Science, Univ Vanderbilt filed Critical Univ Oregon Health & Science

2019-10-28 Application granted granted Critical

2019-10-28 Publication of DK3002298T3 publication Critical patent/DK3002298T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Mycology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK15189714T 2007-11-21 2008-11-21 Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf DK3002298T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98952307P	2007-11-21	2007-11-21
EP08852770.0A EP2222707B1 (en)	2007-11-21	2008-11-21	Anti-factor xi monoclonal antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK3002298T3 true DK3002298T3 (da)	2019-10-28

Family

ID=40568500

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15189714T DK3002298T3 (da)	2007-11-21	2008-11-21	Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
DK08852770.0T DK2222707T3 (da)	2007-11-21	2008-11-21	Monoklonale anti-faktor-XI-antistoffer og fremgangsmåde til anvendelse deraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK08852770.0T DK2222707T3 (da)	2007-11-21	2008-11-21	Monoklonale anti-faktor-XI-antistoffer og fremgangsmåde til anvendelse deraf

Country Status (15)

Country	Link
US (7)	US8236316B2 (da)
EP (2)	EP3002298B1 (da)
JP (1)	JP2011504371A (da)
AU (1)	AU2008326348B2 (da)
CA (1)	CA2705851C (da)
CY (1)	CY1122270T1 (da)
DK (2)	DK3002298T3 (da)
ES (2)	ES2755376T3 (da)
HR (1)	HRP20191999T1 (da)
HU (1)	HUE046564T2 (da)
LT (1)	LT3002298T (da)
PL (1)	PL3002298T3 (da)
PT (1)	PT3002298T (da)
SI (1)	SI3002298T1 (da)
WO (1)	WO2009067660A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2008326348B2 (en) *	2007-11-21	2014-01-30	Oregon Health & Science University	Anti-factor XI monoclonal antibodies and methods of use thereof
PL2297207T3 (pl) *	2008-06-19	2019-03-29	Prothix Bv	Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
CN109797150A (zh)	2008-10-15	2019-05-24	Ionis制药公司	因子11表达的调节
CA2747519C (en)	2008-12-18	2019-04-02	Oregon Health & Science University	Anti-fxi antibodies and methods of use
RU2011146158A (ru) *	2009-04-15	2013-05-27	АйЭсАйЭс ФАРМАСЬЮТИКАЛЗ, ИНК.	Модуляция воспалительных реакций фактором хi
SG10201502587SA (en) *	2010-03-01	2015-06-29	Bayer Healthcare Llc	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2497489A1 (en) *	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
DK2683397T3 (da)	2011-03-09	2017-09-18	Csl Behring Gmbh	Faktor xii inhibitorer til administration til medicinske procedurer omfattende kontakt med kunstige overflader
BR112014027952B1 (pt) *	2012-05-10	2022-06-21	Bayer Pharma Aktiengesellschaft	Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
WO2014089493A1 (en)	2012-12-07	2014-06-12	Vanderbilt University	Antibodies against factor xii and uses thereof
BR112015018077A2 (pt) *	2013-02-01	2017-07-18	Becton Dickinson Co	dispositivos de coleta de sangue que contêm aditivos de inibição de trajeto de contato
WO2014135694A1 (en)	2013-03-08	2014-09-12	Csl Behring Ag	Treatment and prevention of remote ischemia-reperfusion injury
SG11201700473QA (en)	2014-08-07	2017-02-27	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
JOP20200312A1 (ar) *	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en)	2015-07-23	2017-01-26	The Regents Of The University Of California	Antibodies to coagulation factor xia and uses thereof
CN108884169B (zh)	2016-01-22	2022-03-22	默沙东公司	抗凝血因子xi抗体
CA3018124A1 (en) *	2016-03-23	2017-09-28	Prothix Bv	Monoclonal antibodies against the active site of factor xi and uses thereof
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
CN109476758B (zh) *	2016-06-14	2023-05-23	默沙东有限责任公司	抗-凝血因子xi抗体
EP3293593B1 (en) *	2016-09-12	2019-03-20	Sandvik Intellectual Property AB	Method for estimating error propagation
PE20191319A1 (es)	2016-09-20	2019-09-24	Bayer Pharma AG	Anticuerpos novedosos contra el factor xi y sus usos
KR102616666B1 (ko) *	2016-12-23	2023-12-27	노파르티스 아게	인자 xi 항체 및 사용 방법
CA3048157A1 (en) *	2016-12-23	2018-06-28	Novartis Ag	Methods of treatment with anti-factor xi/xia antibodies
US11958911B2 (en)	2017-02-10	2024-04-16	Shanghai Benemae Pharmaceutical	Anti-coagulation factor XI antibody
CN108409863B (zh) *	2017-02-10	2023-09-26	上海仁会生物制药股份有限公司	抗凝血因子xi抗体
CA3083210A1 (en) *	2017-11-22	2018-11-20	Novartis Ag	Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2019217450A1 (en)	2018-05-08	2019-11-14	Rhode Island Hospital	Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
PE20210393A1 (es)	2018-05-09	2021-03-02	Ionis Pharmaceuticals Inc	Compuestos y metodos para la reduccion de la expresion de fxi
JP2021534098A (ja) *	2018-08-09	2021-12-09	上海仁会生物制▲やく▼股▲ふん▼有限公司Shanghai Benemae Pharmaceutical Corporation	抗第ｘｉ因子抗体
CN113474373B (zh)	2019-01-21	2025-09-02	阿罗诺拉股份有限公司	具有抗血栓形成和抗炎作用的新型抗因子xi人源化抗体及其用途
CA3141778A1 (en) *	2019-06-12	2020-12-17	CSL Innovation Pty Ltd	Soluble complement receptor type 1 variant conjugates and uses thereof
AU2021302199A1 (en) *	2020-07-03	2023-02-23	Suzhou Alphamab Co., Ltd.	Coagulation factor XI (FXI) binding protein
EP4644426A1 (en) *	2022-12-30	2025-11-05	Gan & Lee Pharmaceuticals Co., Ltd.	Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1986005807A1 (en)	1985-04-01	1986-10-09	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
WO1989012624A2 (en)	1988-06-14	1989-12-28	Cetus Corporation	Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
IE63847B1 (en)	1989-05-05	1995-06-14	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en)	1990-03-20	2003-02-11	Sherie L. Morrison	Chimeric antibodies with receptor binding ligands in place of their constant region
EP1149913A1 (en)	1990-11-09	2001-10-31	GILLIES, Stephen D.	Cytokine immunoconjugates
FR2686087A1 (fr)	1992-01-13	1993-07-16	Inst Nat Sante Rech Med	Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US20030235587A1 (en) *	1998-08-07	2003-12-25	Feuerstein Giora Z.	Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6623960B1 (en) *	1999-02-12	2003-09-23	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
CN100339132C (zh) *	2000-05-15	2007-09-26	史密丝克莱恩比彻姆公司	抗血栓剂
ATE352040T1 (de)	2000-11-17	2007-02-15	Univ Rochester	In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US7319139B2 (en)	2001-01-29	2008-01-15	Biogen Idec, Inc.	TAG-72 specific CH2 domain deleted antibodies
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20080138837A1 (en) *	2004-07-19	2008-06-12	Robert Greenfield	Methods and kits for detecting and measuring ADAMTS13/FXI complexes
JP5173426B2 (ja) *	2004-10-25	2013-04-03	メルク・シャープ・エンド・ドーム・コーポレイション	抗ａｄｄｌ抗体およびこの使用
US7859456B2 (en)	2006-10-10	2010-12-28	Sirf Technology Holdings, Inc.	Method of mixed data assisted and non data assisted navigation signal acquisition, tracking and reacquisition
JP2010526066A (ja) *	2007-04-23	2010-07-29	シェーリングコーポレイション	抗ｍｄｌ−１抗体
AU2008326348B2 (en)	2007-11-21	2014-01-30	Oregon Health & Science University	Anti-factor XI monoclonal antibodies and methods of use thereof
PL2297207T3 (pl)	2008-06-19	2019-03-29	Prothix Bv	Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
WO2010065275A1 (en)	2008-11-25	2010-06-10	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
SG185777A1 (en)	2010-05-27	2012-12-28	Merck Sharp & Dohme	Soluble guanylate cyclase activators
EP2585055A1 (de)	2010-06-25	2013-05-01	Bayer Intellectual Property GmbH	Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
PH12013500055A1 (en)	2010-07-09	2017-08-23	Bayer Ip Gmbh	Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
US9090610B2 (en)	2011-04-21	2015-07-28	Bayer Intellectual Property Gmbh	Fluoroalkyl-substituted pyrazolopyridines and use thereof
ES2592267T3 (es)	2011-05-06	2016-11-29	Bayer Intellectual Property Gmbh	Imidazopiridinas e imidazopiridazinas sustituidas y su uso
WO2013030138A1 (en)	2011-09-01	2013-03-07	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
JP6054967B2 (ja)	2011-09-02	2016-12-27	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換アネレート化ピリミジンおよびその使用
BR112014027952B1 (pt)	2012-05-10	2022-06-21	Bayer Pharma Aktiengesellschaft	Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor

2008
- 2008-11-21 AU AU2008326348A patent/AU2008326348B2/en not_active Ceased
- 2008-11-21 ES ES15189714T patent/ES2755376T3/es active Active
- 2008-11-21 LT LT15189714T patent/LT3002298T/lt unknown
- 2008-11-21 EP EP15189714.7A patent/EP3002298B1/en not_active Revoked
- 2008-11-21 DK DK15189714T patent/DK3002298T3/da active
- 2008-11-21 ES ES08852770.0T patent/ES2566963T3/es active Active
- 2008-11-21 WO PCT/US2008/084336 patent/WO2009067660A2/en not_active Ceased
- 2008-11-21 JP JP2010535088A patent/JP2011504371A/ja not_active Withdrawn
- 2008-11-21 CA CA2705851A patent/CA2705851C/en not_active Expired - Fee Related
- 2008-11-21 EP EP08852770.0A patent/EP2222707B1/en not_active Not-in-force
- 2008-11-21 HU HUE15189714A patent/HUE046564T2/hu unknown
- 2008-11-21 SI SI200832100T patent/SI3002298T1/sl unknown
- 2008-11-21 DK DK08852770.0T patent/DK2222707T3/da active
- 2008-11-21 US US12/744,037 patent/US8236316B2/en active Active
- 2008-11-21 PL PL15189714T patent/PL3002298T3/pl unknown
- 2008-11-21 PT PT151897147T patent/PT3002298T/pt unknown
2012
- 2012-04-13 US US13/446,320 patent/US8399648B2/en active Active
2013
- 2013-03-04 US US13/783,952 patent/US20130171144A1/en not_active Abandoned
2014
- 2014-04-01 US US14/242,692 patent/US9125895B2/en active Active
2015
- 2015-07-27 US US14/809,551 patent/US9636399B2/en active Active
2017
- 2017-03-27 US US15/470,758 patent/US20170204195A1/en not_active Abandoned
2018
- 2018-07-30 US US16/049,141 patent/US10577428B2/en active Active
2019
- 2019-11-05 HR HRP20191999TT patent/HRP20191999T1/hr unknown
- 2019-11-06 CY CY20191101163T patent/CY1122270T1/el unknown

Also Published As

Publication number	Publication date
CA2705851C (en)	2016-11-01
US9636399B2 (en)	2017-05-02
ES2755376T3 (es)	2020-04-22
EP2222707B1 (en)	2016-01-06
US20150322163A1 (en)	2015-11-12
HRP20191999T1 (hr)	2020-02-07
HUE046564T2 (hu)	2020-03-30
PT3002298T (pt)	2019-11-20
JP2011504371A (ja)	2011-02-10
US20170204195A1 (en)	2017-07-20
CA2705851A1 (en)	2009-05-28
DK2222707T3 (da)	2016-04-11
EP2222707A2 (en)	2010-09-01
EP3002298A1 (en)	2016-04-06
CY1122270T1 (el)	2020-11-25
US8399648B2 (en)	2013-03-19
US20110020349A1 (en)	2011-01-27
US20130171144A1 (en)	2013-07-04
PL3002298T3 (pl)	2020-03-31
US20120276112A1 (en)	2012-11-01
US9125895B2 (en)	2015-09-08
WO2009067660A3 (en)	2009-07-09
AU2008326348A1 (en)	2009-05-28
US20180355057A1 (en)	2018-12-13
LT3002298T (lt)	2019-12-10
WO2009067660A2 (en)	2009-05-28
EP3002298B1 (en)	2019-08-28
HK1223114A1 (en)	2017-07-21
ES2566963T3 (es)	2016-04-18
AU2008326348B2 (en)	2014-01-30
US8236316B2 (en)	2012-08-07
US10577428B2 (en)	2020-03-03
US20140322219A1 (en)	2014-10-30
SI3002298T1 (sl)	2019-12-31

Publication	Publication Date	Title
DK3002298T3 (da)	2019-10-28	Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
DK2907827T3 (da)	2019-01-02	Humaniserede anti-faktor D-antistoffer og anvendelser deraf
DK2118140T3 (da)	2013-07-01	Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2283041T3 (da)	2015-12-07	Humaniserede anti-faktor d-antistoffer og anvendelser deraf
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK1994055T3 (da)	2014-08-25	Anti-5t4-antistoffer og anvendelser deraf
DK2152748T3 (da)	2013-11-04	Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
DK2209806T3 (da)	2012-09-17	Anti-hepcidin-antistoffer og anvendelser deraf
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK2474557T3 (da)	2014-11-10	Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
DK2059535T3 (da)	2014-01-13	Prlr-specifikt antistof og anvendelser deraf
PL3059246T3 (pl)	2018-11-30	Zmodyfikowany region stały przeciwciała
DK3401334T3 (da)	2023-03-27	Monoklonale antistoffer mod claudin-18 til cancerbehandling
NO344963B1 (no)	2020-08-03	Humanisert antistoff
BRPI0822447A2 (pt)	2015-06-16	Anticorpo monoclonal e método do mesmo
HUE038501T2 (hu)	2018-10-29	Antitest készítmények
BRPI0914943A2 (pt)	2013-09-17	anticorpos de il-6 e sua utilizaÇço
DK2068887T3 (da)	2014-05-19	SP35-antistoffer og anvendelser heraf
DK2209375T3 (da)	2014-10-06	Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK3091034T3 (da)	2020-06-15	Anti-CD40-antistoffer og anvendelser deraf
DK1996625T3 (da)	2011-11-28	Anti-Tat226 antistoffer og immunkonjugater
DK2061814T3 (da)	2012-08-27	Antistoffer og immunokonjugater og anvendelse deraf.
BRPI0820298A2 (pt)	2017-04-04	anticorpos anti-vegf composições e métodos
IL196470A (en)	2016-07-31	Antagonist antibody for the treatment of cancer
PL2488551T3 (pl)	2019-01-31	Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania